{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-21-000041","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2021-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.112717+00:00","generated_at":"2026-06-29T03:49:10.191853+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Travere Therapeutics appoints Ruth Williams-Brinkley to Board of Directors","bullets":["Board expanded from 10 to 11; Ms. Williams-Brinkley elected effective Sept 14, 2021.","Received initial grant: option for 15,750 shares and RSU for 5,250 shares, vesting over 3 years.","Annual retainer of $50,000; subsequent annual grants of option for 9,000 shares and RSU for 3,000 shares.","She is President of Kaiser Foundation Health Plan (Mid-Atlantic); Travere had ~$4.9M gross revenue from Kaiser (Jan 2020–Jun 2021).","Board determined Ms. Williams-Brinkley qualifies as independent under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-21-000041","json":"https://secwatch.observer/filing/0001438533-21-000041.json","markdown":"https://secwatch.observer/filing/0001438533-21-000041.md","text":"https://secwatch.observer/filing/0001438533-21-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000041/0001438533-21-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000041/tvtx-20210914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:49:10.191853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52b4949ce4","claim":"Ruth Williams-Brinkley was elected as Director at Travere Therapeutics, Inc..","evidence_excerpt":"On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved an increase in the size of the Board of Directors from 10 to 11 members and elected Ruth Williams-Brinkley to serve as a director of the Company, effective September 14, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853321000041/0001438533-21-000041-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}